{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:13:41Z","timestamp":1788880421637,"version":"build-2803163510"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Insomnia symptoms in major depressive disorder (MDD) are clinically heterogeneous, ranging from presleep rumination and prolonged sleep latency to repeated nocturnal awakenings and early-morning awakening. Their clinical significance and treatment implications may also differ between active MDD and residual insomnia symptoms during partial remission. This narrative review examines how these presentations may inform the use of sedating antidepressants and dual orexin receptor antagonists (DORAs). Sedating antidepressants, including mirtazapine, trazodone, doxepin, and other tricyclic antidepressants, differ in dose-dependent antidepressant activity, receptor profile, and adverse-effect burden. DORAs directly target orexin-mediated wake drive and have the strongest evidence for insomnia disorder, particularly sleep-maintenance outcomes, although evidence in active MDD remains limited. Because clinical presentations neither establish an underlying mechanism nor reliably predict treatment response, the proposed framework should be used as a hypothesis-generating aid rather than a validated treatment algorithm. Pharmacological selection should also consider suicide risk, substance-use history, comorbid sleep disorders, concomitant central nervous system depressants, and next-day functioning.<\/jats:p>","DOI":"10.3389\/fpsyt.2026.1928430","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:02:24Z","timestamp":1788879744000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological modulation of hyperarousal in insomnia associated with major depressive disorder: a narrative review of sedating antidepressants and orexin receptor antagonists"],"prefix":"10.3389","volume":"17","author":[{"given":"Yiwei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Rehabilitation Medicine, Peking University Shougang Hospital","place":["Beijing, China"]},{"name":"Department of Sports and Health, Tianjin University of Sport","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Peking University Shougang Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingkai","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Peking University Shougang Hospital","place":["Beijing, China"]},{"name":"Department of Sports and Health, Tianjin University of Sport","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Peking University Shougang Hospital","place":["Beijing, China"]},{"name":"Department of Sports and Health, Tianjin University of Sport","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Peking University Shougang Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.70089","article-title":"The prevalence of insomnia disorder in the general population: a meta-analysis","volume":"34","author":"Van Straten","year":"2025","journal-title":"J Sleep Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60750-2","article-title":"Chronic insomnia","volume":"379","author":"Morin","year":"2012","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/smrv.2002.0186","article-title":"Epidemiology of insomnia: what we know and what we still need to learn","volume":"6","author":"Ohayon","year":"2002","journal-title":"Sleep Med Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2005.08.008","article-title":"Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors","volume":"7","author":"Morin","year":"2006","journal-title":"Sleep Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.5664\/jcsm.26929","article-title":"Insomnia: definition, prevalence, etiology, and consequences","volume":"3","author":"Roth","year":"2007","journal-title":"J Clin Sleep Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/28.11.1457","article-title":"Epidemiology of insomnia, depression, and anxiety","volume":"28","author":"Taylor","year":"2005","journal-title":"Sleep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2008.10.3\/dnutt","article-title":"Sleep disorders as core symptoms of depression","volume":"10","author":"Nutt","year":"2008","journal-title":"Dialogues Clin Neurosci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2011.01.011","article-title":"Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies","volume":"135","author":"Baglioni","year":"2011","journal-title":"J Affect Disord"},{"key":"B9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0022-3956(02)00052-3","article-title":"Place of chronic insomnia in the course of depressive and anxiety disorders","volume":"37","author":"Ohayon","year":"2003","journal-title":"J Psychiatr Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1468212","article-title":"Advances in the research of comorbid insomnia and depression: mechanisms, impacts, and interventions","volume":"16","author":"Gao","year":"2025","journal-title":"Front Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115658","article-title":"Insomnia and the incidence, recurrence and persistence of common mental disorders: sex differences in the general population","volume":"331","author":"Luik","year":"2024","journal-title":"Psychiatry Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12883-022-02869-x","article-title":"Effect of insomnia in the major depressive disorder","volume":"22","author":"Xu","year":"2022","journal-title":"BMC Neurol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12888-016-1075-3","article-title":"Insomnia and the risk of depression: a meta-analysis of prospective cohort studies","volume":"16","author":"Li","year":"2016","journal-title":"BMC Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41572-026-00693-y","article-title":"Insomnia disorder","volume":"12","author":"Spiegelhalder","year":"2026","journal-title":"Nat Rev Dis Primers"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14170","article-title":"Depression in sleep disturbance: a review on a bidirectional relationship, mechanisms and treatment","volume":"23","author":"Fang","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsad104","article-title":"Does insomnia treatment prevent depression","volume":"46","author":"Boland","year":"2023","journal-title":"Sleep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14010050","article-title":"Neurobiological underpinnings of hyperarousal in depression: a comprehensive review","volume":"14","author":"Xie","year":"2024","journal-title":"Brain Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1037\/bul0000053","article-title":"Sleep and mental disorders: a meta-analysis of polysomnographic research","volume":"142","author":"Baglioni","year":"2016","journal-title":"Psychol Bull"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.893015","article-title":"Pharmacotherapeutic management of insomnia and effects on sleep processes, neural plasticity, and brain systems modulating stress: a narrative review","volume":"16","author":"Palagini","year":"2022","journal-title":"Front Neurosci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.36131\/cnfioritieditore20240504","article-title":"Effects of approved pharmacological interventions for insomnia on mood disorders: a systematic review","volume":"21","author":"Palagini","year":"2024","journal-title":"Clin Neuropsychiatry"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.6470","article-title":"Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline","volume":"13","author":"Sateia","year":"2017","journal-title":"J Clin Sleep Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2175","article-title":"Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians","volume":"165","author":"Qaseem","year":"2016","journal-title":"Ann Intern Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.14035","article-title":"The European Insomnia Guideline: an update on the diagnosis and treatment of insomnia 2023","volume":"32","author":"Riemann","year":"2023","journal-title":"J Sleep Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11920-017-0816-4","article-title":"Effects of antidepressants on sleep","volume":"19","author":"Wichniak","year":"2017","journal-title":"Curr Psychiatry Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41398-025-03439-8","article-title":"Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis","volume":"15","author":"Kishi","year":"2025","journal-title":"Transl Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00436-1","article-title":"Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials","volume":"21","author":"Mignot","year":"2022","journal-title":"Lancet Neurol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-025-06773-3","article-title":"Comparison of efficacy and safety of dual orexin receptor antagonists lemborexant and daridorexant for the treatment of insomnia: a systematic review and meta-analysis","volume":"242","author":"Tang","year":"2025","journal-title":"Psychopharmacology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00021-6","article-title":"The neurobiology, investigation, and treatment of chronic insomnia","volume":"14","author":"Riemann","year":"2015","journal-title":"Lancet Neurol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13928","article-title":"Hyperarousal in insomnia disorder: current evidence and potential mechanisms","volume":"32","author":"Dressle","year":"2023","journal-title":"J Sleep Res"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-54359-4","volume-title":"Sleep Neurology: A Comprehensive Guide to Basic and Clinical Aspects","author":"DelRosso","year":"2021"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddmod.2011.07.002","article-title":"A neurobiological model of insomnia","volume":"8","author":"Buysse","year":"2011","journal-title":"Drug Discov Today Dis Models"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13406","article-title":"Hypocretins (orexins): the ultimate translational neuropeptides","volume":"291","author":"Jacobson","year":"2022","journal-title":"J Intern Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178700","article-title":"Targeting the orexin system in the pharmacological management of insomnia and other diseases: suvorexant, lemborexant, daridorexant, and novel experimental agents","volume":"26","author":"\u017be\u0142abowski","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsad177","article-title":"Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis","volume":"46","author":"Zhou","year":"2023","journal-title":"Sleep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmen.0000531","article-title":"Sleep and psychiatric disorders: bidirectional interactions and shared neurobiological mechanisms","volume":"2","author":"Hyndych","year":"2025","journal-title":"PloS Ment Health"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.125.325686","article-title":"Insomnia phenotypes, cardiovascular risk and their link to brain health","volume":"137","author":"Fernandez-Mendoza","year":"2025","journal-title":"Circ Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13910","article-title":"Insomnia nosology: a systematic review and critical appraisal of historical diagnostic categories and current phenotypes","volume":"32","author":"Nyhuis","year":"2023","journal-title":"J Sleep Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s42003-025-07794-6","article-title":"A continuous approach to explain insomnia and subjective-objective sleep discrepancy","volume":"8","author":"Herzog","year":"2025","journal-title":"Commun Biol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/jsr.12594","article-title":"European guideline for the diagnosis and treatment of insomnia","volume":"26","author":"Riemann","year":"2017","journal-title":"J Sleep Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10020071","article-title":"Acute and chronic insomnia: what has time and\/or hyperarousal got to do with it","volume":"10","author":"Vargas","year":"2020","journal-title":"Brain Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/10253890701378967","article-title":"HPA axis and sleep: identifying subtypes of major depression: review","volume":"11","author":"Antonijevic","year":"2008","journal-title":"Stress"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.10704","article-title":"Daytime autonomic nervous system functions differ among adults with and without insomnia symptoms","volume":"19","author":"McCall","year":"2023","journal-title":"J Clin Sleep Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.14256","article-title":"Hyperarousal features in the sleep architecture of individuals with and without insomnia","volume":"34","author":"Di Marco","year":"2025","journal-title":"J Sleep Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2026.121378","article-title":"Management of insomnia symptoms in depressed patients treated with agomelatine, mirtazapine and trazodone: a systematic review and meta-analysis","volume":"402","author":"Zhang","year":"2026","journal-title":"J Affect Disord"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01110-2","article-title":"Effects of trazodone on sleep: a systematic review and meta-analysis","volume":"38","author":"Kokkali","year":"2024","journal-title":"CNS Drugs"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)00882-9","article-title":"Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study","volume":"48","author":"Winokur","year":"2000","journal-title":"Biol Psychiatry"},{"key":"B47","first-page":"24","article-title":"Trazodone for insomnia: a systematic review","volume":"14","author":"Jaffer","year":"2017","journal-title":"Innov Clin Neurosci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41398-024-03087-4","article-title":"Orexin receptor antagonists in the treatment of insomnia associated with psychiatric disorders: a systematic review","volume":"14","author":"Kishi","year":"2024","journal-title":"Transl Psychiatry"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.12.008","article-title":"Efficacy of orexin antagonists for the management of major depressive disorder: a systematic review of randomized clinical trials","volume":"372","author":"Meshkat","year":"2025","journal-title":"J Affect Disord"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1768667","article-title":"Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis","volume":"81","author":"Rocha","year":"2023","journal-title":"Arq Neuropsiquiatr"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.6116","article-title":"Suvorexant in patients with insomnia: pooled analyses of three-month data from phase-3 randomized controlled clinical trials","volume":"12","author":"Herring","year":"2016","journal-title":"J Clin Sleep Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18254","article-title":"Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial","volume":"2","author":"Rosenberg","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12509","article-title":"Efficacy and safety of lemborexant in subjects with insomnia treated with medications for depression\/anxiety symptoms","volume":"45","author":"Krystal","year":"2025","journal-title":"Neuropsychopharmacol Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsae098","article-title":"Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder: a pooled post hoc analysis of two randomized phase 3 clinical studies","volume":"47","author":"Di Marco","year":"2024","journal-title":"Sleep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.9150","article-title":"Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder","volume":"17","author":"Moline","year":"2021","journal-title":"J Clin Sleep Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2026.2639557","article-title":"Daridorexant: exploring its role in the treatment of insomnia disorder","volume":"26","author":"Winter","year":"2026","journal-title":"Expert Rev Neurother"},{"key":"B58","unstructured":"Rahway, NJ\n          Merck Sharp & Dohme LLC\n          BELSOMRA (Suvorexant) Tablets, for Oral Use, C-IV: Prescribing Information [Internet]\n          \n          2025"},{"key":"B59","unstructured":"Nutley, NJ\n          Eisai Inc\n          DAYVIGO (Lemborexant) Tablets, for Oral Use, CIV: Prescribing Information [Internet]\n          \n          2025"},{"key":"B60","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s44470-025-00038-8","article-title":"Combination treatment for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline","volume":"22","author":"Buysse","year":"2026","journal-title":"J Clin Sleep Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/31.4.489","article-title":"Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia","volume":"31","author":"Manber","year":"2008","journal-title":"Sleep"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.09.017","article-title":"Cognitive behavioral therapy for insomnia to treat major depressive disorder with comorbid insomnia: a systematic review and meta-analysis","volume":"367","author":"Furukawa","year":"2024","journal-title":"J Affect Disord"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12841","article-title":"The key role of insomnia and sleep loss in the dysregulation of multiple systems involved in mood disorders: a proposed model","volume":"28","author":"Palagini","year":"2019","journal-title":"J Sleep Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.8986","article-title":"Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline","volume":"17","author":"Edinger","year":"2021","journal-title":"J Clin Sleep Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1177\/07067437251322401","article-title":"Incidence of major depressive disorder relapse and effectiveness of pharmacologic and psychological interventions in primary care: a systematic review and meta-analysis","volume":"70","author":"Abu-Ashour","year":"2025","journal-title":"Can J Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1928430\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:02:28Z","timestamp":1788879748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1928430\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":65,"alternative-id":["10.3389\/fpsyt.2026.1928430"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1928430","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1928430"}}